RESEARCH UNIT IN PEDIATRIC VACCINES
GALLEGO GROUP GENETICS, VACCINES AND RESEARCH PEDIATRIC (G3VIP)
Research Team Santiago | |
Coordinator: | Federico Martinón-Torres |
Researchers: |
Lorenzo Redondo Collazo
Jose María Martinón Sánchez Carmen Rodríguez-Tenreiro Sánchez Marta Bouzón Alejandro Silvia Rodríguez Blanco Nazareth Martinón Torres Natalia García Sánchez Manoel Muñiz Fontan |
Research Nurses: |
Mª Dolores Oreiro Vilacoba
Luisa García Vicente |
Secretariat: | Belen Mosquera Perez |
An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation (phase 1b) of oseltamivir (Tamiflu®) in the treatment of infants 0 to < 12 months of age with confirmed influenza infection (protocol WP22849) | |
---|---|
Type of test: | fase 1, multicéntrico, internacional |
Duration: | 2010 A 2012 |
Promotor: | Roche |
Status: | Inicio de reclutamiento febrero de 2010 |
Contact: | F. Martinón (Coordinator) o L. Redondo (investigador principal) |
A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12A | |
---|---|
Type of participation: | Asesor, Consultor, Coordinator nacional, Coordinator regional, e investigador principal |
Duration: | 2010 a 2012 |
Promotor: | Novartis |
Code: | V72P12E1 |
Contact: | F. Martinón (Coordinator) o L. Redondo (investigador principal) |
A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain (protocolo 6096A1-501) | |
---|---|
Duration: | 2005 a 2008-2009 |
Promotor: | Wyeth |
Status: | Fase de cierre y publicación de resultados |
Contact: | F. Martinón (Coordinator regional) |
An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured with rHA when administered to Children in their Second Year of Life | |
---|---|
Duration: | 2007 a 2009 |
Promotor: | Sanofi Pasteur MSD |
Status: | fase de cierre y publicación de resultados |
Contact: | F. Martinón (Coordinator regional) o L. Redondo (investigador principal) |
A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid ConjugateVaccine and Other Routine Pediatric Vaccinations in Spain (protocol 6096A1-3007) | |
---|---|
Duration: | 2007 a 2009 |
Promotor: | Wyeth |
Status: | fase de cierre y publicación de resultados |
Contact: | F. Martinón (lead investigator y Coordinator regional) |
A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-Old Children and in 2 Month Old Infants | |
---|---|
Duration: | 2009 a 2011 |
Promotor: | Medimmune |
Status: | Inicio de reclutamiento Abril 2009 |
Contact: | F. Martinón (Coordinator nacional) o L. Redondo (investigador principal) |
A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with or without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules (protocolo V72P12) | |
---|---|
Duration: | 2009 a 2011 |
Promotor: | Novartis |
Status: | Activo |
Contact: | F. Martinón (Coordinator nacional) |
A Single blind, Randomized Phase 1/2 Trial of the Safety, Tolerability, and Immunogenicity of Meningococcal Group B rLP2086 Vaccine in Healthy Infants (protocolo 6108K2-2000) | |
---|---|
Duration: | 2009 al 2013 |
Promotor: | Wyeth |
Status: | Activo |
Contact: | F. Martinón (Coordinator nacional) o L. Redondo (Investigador principal) |
A Single blind, Randomized Phase 2 Trial of the Safety, Tolerability, and Immunogenicity of Meningococcal Group B rLP2086 Vaccine at dose of 60 microg, 120 microg y 200 microgr in Healthy Adolescentes aged 11 to 18 years (protocolo 6108a1-2001) | |
---|---|
Duration: | 2009 al 2013 |
Promotor: | Wyeth |
Status: | Inicio de reclutamiento Junio 2009 |
Contact: | F. Martinón (Coordinator nacional) o L. Redondo (investigador principal) |